Trial Profile
An Open-label, Multicenter, Phase 2 trial of selinexor (KPT-330), bortezomib and low-dose dexamethasone plus daratumumab (SELIBORDARA) for the treatment of patients with refractory or relapsed and refractory multiple myeloma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Aug 2023
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Daratumumab (Primary) ; Dexamethasone (Primary) ; Selinexor (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms GEM-SELIBORDARA
- 15 Jun 2023 Updated results (n=57) assessing and safety of selinexor with D-Vd for the treatment of RRMM in a phase 2,multicenter, open label study presented at the 28th Congress of the European Haematology Association
- 14 Dec 2021 Interim Results of Selinexor in Combination with Daratumumab-Bortezomib and Dexamethasone for the Treatment of Relapse or Refractory Multiple Myeloma, presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 04 Nov 2021 According to a Karyopharm Therapeutics media release, initial data from the study will be presented at the upcoming American Society of Hematology (ASH) 2021 Annual Meeting and Exposition.